How Big Will the SpaceX IPO Be?
Operated up to now as a private business, SpaceX will…
Sell
15
NCNA Quote, Financials, Valuation and Earnings
Last price:
$2.54
Seasonality move
:
-2.45%
Day range:
$2.67 - $2.94
52-week range:
$2.67 - $268.00
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
0.56x
Volume:
167K
Avg. volume:
80.6K
1-year change:
-98.78%
Market cap:
$11.3M
Revenue:
--
EPS (TTM):
-$163.37
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
NCNA
NuCana Plc
|
-- | -$0.01 | -- | -99.69% | $104.00 |
|
AUTL
Autolus Therapeutics Plc
|
$24.1M | -$0.41 | 199.85% | -6.42% | $9.30 |
|
BCYC
Bicycle Therapeutics Plc
|
$7.1M | -$0.94 | -27.61% | -7.34% | $21.50 |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -- | -- | $17.94 |
|
DBVT
DBV Technologies SA
|
$1.2M | -$0.22 | -- | -86.12% | $39.69 |
|
MREO
Mereo BioPharma Group Plc
|
$7.1M | -$0.01 | -100% | -75.07% | $3.45 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
NCNA
NuCana Plc
|
$2.71 | $104.00 | $11.3M | -- | $0.00 | 0% | -- |
|
AUTL
Autolus Therapeutics Plc
|
$1.43 | $9.30 | $380.6M | -- | $0.00 | 0% | 7.43x |
|
BCYC
Bicycle Therapeutics Plc
|
$6.52 | $21.50 | $452.3M | -- | $0.00 | 0% | 15.94x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
$1.84 | $17.94 | $1.5M | -- | $0.00 | 0% | 0.73x |
|
DBVT
DBV Technologies SA
|
$22.96 | $39.69 | $628.2M | -- | $0.00 | 0% | -- |
|
MREO
Mereo BioPharma Group Plc
|
$0.44 | $3.45 | $70M | -- | $0.00 | 0% | 137.39x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
NCNA
NuCana Plc
|
0.52% | -0.467 | 0.95% | 4.03x |
|
AUTL
Autolus Therapeutics Plc
|
55.06% | 2.916 | 74.96% | 4.83x |
|
BCYC
Bicycle Therapeutics Plc
|
1.04% | 1.504 | 1.21% | 9.36x |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | 3.608 | -- | 1.20x |
|
DBVT
DBV Technologies SA
|
23.24% | -3.671 | 5.85% | 1.41x |
|
MREO
Mereo BioPharma Group Plc
|
0.85% | 1.603 | 0.12% | 8.09x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
NCNA
NuCana Plc
|
-$93K | -$4.8M | -281.73% | -286.82% | -- | $1.5M |
|
AUTL
Autolus Therapeutics Plc
|
-$10.8M | -$71.2M | -32.68% | -59.51% | -337.93% | -$79.9M |
|
BCYC
Bicycle Therapeutics Plc
|
$9.9M | -$72.9M | -33.96% | -34.37% | -624.9% | -$71.3M |
|
BDRX
Biodexa Pharmaceuticals Plc
|
-- | -- | -160.77% | -160.77% | -- | -- |
|
DBVT
DBV Technologies SA
|
-$4.3M | -$36.9M | -211.46% | -280.59% | -- | -$32.5M |
|
MREO
Mereo BioPharma Group Plc
|
-- | -$10.3M | -67.41% | -70.81% | -2099.86% | -$7.3M |
NuCana Plc vs. Competitors
-
Which has Higher Returns NCNA or AUTL?
Autolus Therapeutics Plc has a net margin of -- compared to NuCana Plc's net margin of -373.3%. NuCana Plc's return on equity of -286.82% beat Autolus Therapeutics Plc's return on equity of -59.51%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M AUTLAutolus Therapeutics Plc-51.21% -$0.30 $590.6M -
What do Analysts Say About NCNA or AUTL?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 767427.68%. On the other hand Autolus Therapeutics Plc has an analysts' consensus of $9.30 which suggests that it could grow by 550.35%. Given that NuCana Plc has higher upside potential than Autolus Therapeutics Plc, analysts believe NuCana Plc is more attractive than Autolus Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 AUTLAutolus Therapeutics Plc9 0 0 -
Is NCNA or AUTL More Risky?
NuCana Plc has a beta of 1.602, which suggesting that the stock is 60.248% more volatile than S&P 500. In comparison Autolus Therapeutics Plc has a beta of 2.012, suggesting its more volatile than the S&P 500 by 101.185%.
-
Which is a Better Dividend Stock NCNA or AUTL?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Autolus Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Autolus Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or AUTL?
NuCana Plc quarterly revenues are --, which are smaller than Autolus Therapeutics Plc quarterly revenues of $21.1M. NuCana Plc's net income of -$378.9K is higher than Autolus Therapeutics Plc's net income of -$78.6M. Notably, NuCana Plc's price-to-earnings ratio is -- while Autolus Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 7.43x for Autolus Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K AUTLAutolus Therapeutics Plc7.43x -- $21.1M -$78.6M
-
Which has Higher Returns NCNA or BCYC?
Bicycle Therapeutics Plc has a net margin of -- compared to NuCana Plc's net margin of -503.67%. NuCana Plc's return on equity of -286.82% beat Bicycle Therapeutics Plc's return on equity of -34.37%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M BCYCBicycle Therapeutics Plc85.04% -$0.85 $625M -
What do Analysts Say About NCNA or BCYC?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 767427.68%. On the other hand Bicycle Therapeutics Plc has an analysts' consensus of $21.50 which suggests that it could grow by 229.76%. Given that NuCana Plc has higher upside potential than Bicycle Therapeutics Plc, analysts believe NuCana Plc is more attractive than Bicycle Therapeutics Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 BCYCBicycle Therapeutics Plc6 4 0 -
Is NCNA or BCYC More Risky?
NuCana Plc has a beta of 1.602, which suggesting that the stock is 60.248% more volatile than S&P 500. In comparison Bicycle Therapeutics Plc has a beta of 1.524, suggesting its more volatile than the S&P 500 by 52.42%.
-
Which is a Better Dividend Stock NCNA or BCYC?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Bicycle Therapeutics Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Bicycle Therapeutics Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BCYC?
NuCana Plc quarterly revenues are --, which are smaller than Bicycle Therapeutics Plc quarterly revenues of $11.7M. NuCana Plc's net income of -$378.9K is higher than Bicycle Therapeutics Plc's net income of -$58.7M. Notably, NuCana Plc's price-to-earnings ratio is -- while Bicycle Therapeutics Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 15.94x for Bicycle Therapeutics Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K BCYCBicycle Therapeutics Plc15.94x -- $11.7M -$58.7M
-
Which has Higher Returns NCNA or BDRX?
Biodexa Pharmaceuticals Plc has a net margin of -- compared to NuCana Plc's net margin of --. NuCana Plc's return on equity of -286.82% beat Biodexa Pharmaceuticals Plc's return on equity of -160.77%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M BDRXBiodexa Pharmaceuticals Plc-- -- $6M -
What do Analysts Say About NCNA or BDRX?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 767427.68%. On the other hand Biodexa Pharmaceuticals Plc has an analysts' consensus of $17.94 which suggests that it could grow by 9565.83%. Given that NuCana Plc has higher upside potential than Biodexa Pharmaceuticals Plc, analysts believe NuCana Plc is more attractive than Biodexa Pharmaceuticals Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 BDRXBiodexa Pharmaceuticals Plc1 0 0 -
Is NCNA or BDRX More Risky?
NuCana Plc has a beta of 1.602, which suggesting that the stock is 60.248% more volatile than S&P 500. In comparison Biodexa Pharmaceuticals Plc has a beta of 0.952, suggesting its less volatile than the S&P 500 by 4.8%.
-
Which is a Better Dividend Stock NCNA or BDRX?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Biodexa Pharmaceuticals Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Biodexa Pharmaceuticals Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or BDRX?
NuCana Plc quarterly revenues are --, which are larger than Biodexa Pharmaceuticals Plc quarterly revenues of --. NuCana Plc's net income of -$378.9K is higher than Biodexa Pharmaceuticals Plc's net income of --. Notably, NuCana Plc's price-to-earnings ratio is -- while Biodexa Pharmaceuticals Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 0.73x for Biodexa Pharmaceuticals Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K BDRXBiodexa Pharmaceuticals Plc0.73x -- -- --
-
Which has Higher Returns NCNA or DBVT?
DBV Technologies SA has a net margin of -- compared to NuCana Plc's net margin of --. NuCana Plc's return on equity of -286.82% beat DBV Technologies SA's return on equity of -280.59%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M DBVTDBV Technologies SA-- -$1.21 $68.9M -
What do Analysts Say About NCNA or DBVT?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 767427.68%. On the other hand DBV Technologies SA has an analysts' consensus of $39.69 which suggests that it could grow by 72.58%. Given that NuCana Plc has higher upside potential than DBV Technologies SA, analysts believe NuCana Plc is more attractive than DBV Technologies SA.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 DBVTDBV Technologies SA4 0 1 -
Is NCNA or DBVT More Risky?
NuCana Plc has a beta of 1.602, which suggesting that the stock is 60.248% more volatile than S&P 500. In comparison DBV Technologies SA has a beta of -1.166, suggesting its less volatile than the S&P 500 by 216.581%.
-
Which is a Better Dividend Stock NCNA or DBVT?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DBV Technologies SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. DBV Technologies SA pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or DBVT?
NuCana Plc quarterly revenues are --, which are smaller than DBV Technologies SA quarterly revenues of --. NuCana Plc's net income of -$378.9K is higher than DBV Technologies SA's net income of -$33M. Notably, NuCana Plc's price-to-earnings ratio is -- while DBV Technologies SA's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus -- for DBV Technologies SA. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K DBVTDBV Technologies SA-- -- -- -$33M
-
Which has Higher Returns NCNA or MREO?
Mereo BioPharma Group Plc has a net margin of -- compared to NuCana Plc's net margin of -2923.31%. NuCana Plc's return on equity of -286.82% beat Mereo BioPharma Group Plc's return on equity of -70.81%.
Company Gross Margin Earnings Per Share Invested Capital NCNANuCana Plc-- -$0.13 $35.1M MREOMereo BioPharma Group Plc14% -$0.04 $47M -
What do Analysts Say About NCNA or MREO?
NuCana Plc has a consensus price target of $104.00, signalling upside risk potential of 767427.68%. On the other hand Mereo BioPharma Group Plc has an analysts' consensus of $3.45 which suggests that it could grow by 500.42%. Given that NuCana Plc has higher upside potential than Mereo BioPharma Group Plc, analysts believe NuCana Plc is more attractive than Mereo BioPharma Group Plc.
Company Buy Ratings Hold Ratings Sell Ratings NCNANuCana Plc0 1 0 MREOMereo BioPharma Group Plc4 2 0 -
Is NCNA or MREO More Risky?
NuCana Plc has a beta of 1.602, which suggesting that the stock is 60.248% more volatile than S&P 500. In comparison Mereo BioPharma Group Plc has a beta of 0.358, suggesting its less volatile than the S&P 500 by 64.214%.
-
Which is a Better Dividend Stock NCNA or MREO?
NuCana Plc has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Mereo BioPharma Group Plc offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. NuCana Plc pays -- of its earnings as a dividend. Mereo BioPharma Group Plc pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios NCNA or MREO?
NuCana Plc quarterly revenues are --, which are smaller than Mereo BioPharma Group Plc quarterly revenues of --. NuCana Plc's net income of -$378.9K is higher than Mereo BioPharma Group Plc's net income of -$7M. Notably, NuCana Plc's price-to-earnings ratio is -- while Mereo BioPharma Group Plc's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for NuCana Plc is -- versus 137.39x for Mereo BioPharma Group Plc. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income NCNANuCana Plc-- -- -- -$378.9K MREOMereo BioPharma Group Plc137.39x -- -- -$7M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Where Will ISRG Stock Be in 5 Years?
Intuitive Surgical (NASDAQ:ISRG) is the innovative medical tech business behind…
Is Kratos Stock a Good Investment?
UAV and hypersonic system defense contractor Kratos (NASDAQ:KTOS) has swung…
Stock Ideas
Buy
59
Is NVDA Stock a Buy?
Market Cap: $4.7T
P/E Ratio: 66x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 42x
Alerts
Buy
78
GDXU alert for Jan 30
MicroSectors Gold Miners 3X Leveraged ETN [GDXU] is down 38.85% over the past day.
Buy
67
PFSI alert for Jan 30
PennyMac Financial Services, Inc. [PFSI] is down 33.21% over the past day.
Buy
88
JNUG alert for Jan 30
Direxion Daily Junior Gold Miners Idx Bull 2X Shs [JNUG] is down 26.98% over the past day.
